LENVALIEVA 10 mg contains Lenvatinib, an oral multi-targeted tyrosine kinase inhibitor (TKI). It blocks receptors involved in tumor angiogenesis and growth, including VEGFR 1–3, FGFR 1–4, PDGFR-α, RET, and KIT, leading to inhibition of tumor blood vessel formation and cancer cell proliferation. 

Lenvatinib is indicated for:

1. Differentiated Thyroid Cancer (DTC)
     – Radioiodine-refractory disease

2. Hepatocellular Carcinoma (HCC)
     – Unresectable or advanced disease (first-line)

3. Renal Cell Carcinoma (RCC)
     – In combination with Everolimus after prior VEGF therapy

4. Endometrial Carcinoma
     – In combination with Pembrolizumab for advanced disease

Common side effects:

•   Hypertension

•    Diarrhea

•    Fatigue

•    Loss of appetite, weight loss

•    Nausea, vomiting

Serious side effects:

•   Severe hypertension

•   Proteinuria

•   Cardiac dysfunction

•    Hepatic impairment

•    Gastrointestinal perforation (rare)

Regular blood pressure, urine protein, and liver function monitoring is required.

Dose depends on cancer type, body weight, and tolerance.

Standard adult doses:

•  Thyroid cancer: 24 mg once daily

•   Hepatocellular carcinoma:
    – ≥60 kg: 12 mg once daily
    – <60 kg: 8 mg once daily

•   RCC / Endometrial cancer (combination therapy): 18–20 mg once daily

10 mg capsules are commonly used to achieve the required daily dose and for dose adjustments.

NOTE: This medicine should be taken only under a doctor’s supervision.